PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.

Accurate calculation of prostate-specific antigen doubling time can be crucial for prostate cancer treatment decisions but is ...

Embark Small Cap Equity Fund earns a Below Average Process Pillar rating. The process is bolstered by the size of its portfolio management team. With four portfolio managers at the helm, the fund ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Devaki Surasi discussing combination sequencing for PSMA-based therapy in advanced disease. Dr. Surasi started with ...

This is a retrospective, observational, multicenter, longitudinal follow-up study to describe the treatment patterns received by the Spanish patients who received darolutamide in the ARAMIS study, ...

AI-driven prediction of prostate cancer risk: A comparative analysis with C the Signs in the Mayo Clinic data platform. Pattern of presentations of BCR, and high-risk BCR according to EAU and EMBARK ...